CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for CRISPR Therapeutics in a report ...

Agilent Technologies Inc. and Synthego Corp. sparred Friday over whether Agilent patents related to a key component of the ...

ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

The company’s first approved product, CASGEVY, is a groundbreaking CRISPR/Cas9 gene-edited therapy for sickle cell disease and transfusion-dependent beta-thalassemia. This historic approval in ...

The stock option granted on November 5, 2024 has a ten-year term and an exercise price of $3.59 per share, which is equal to ...

Investors in CRISPR Therapeutics AG (NASDAQ:CRSP) have tasted that bitter downside in the last year, as the share price dropped 46%. That contrasts poorly with the market return of 15%. At least the ...

Spread the love Table of Contents Introduction Methodology Top 10 Biotech Giants Rising Stars (11-25) Innovators and ...

The mice were created by Colossal Biosciences, which edits DNA for species conservation, and has been working to bring back ...

In fact, bioethicists warned about such “frivolous” uses of CRISPR a decade ago when the technology was in its infancy. The company’s glowing rabbits will be an initial test to see how ...